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Medicine in the Young (Part 1)  
Maurice Hall and Lezley-Anne Hanna 
Lecturer (Education) and Senior Lecturer (Education), respectively; Queen’s University Belfast 
 
After completing this part of the module you will: 
• know about the various stages of development, from birth through to adolescent (including 
the key terms and accepted ages) 
• appreciate pharmacokinetic changes that occur in neonates  
• appreciate pharmacokinetic changes that occur in infants  
• appreciate pharmacokinetic changes that occur in children  
 
Introduction 
The aim of this article (Part 1) is to outline the important pharmacokinetic characteristics in the 
developing child that need to be accounted for when using medicines in children. Having a 
fundamental knowledge of these pharmacokinetic factors is important in ensuring that medicines are 
used safely and effectively. In the next article (Part 2), we will focus specifically on the use of medicines 
in children, looking particularly at factors pharmacists should consider when providing over-the-
counter medicines for use in children.  
 
The use of medicines in the young covers the time from birth through to when the development into 
an adult is complete. There are various stages defined in medical literature, with the following terms 
and ages being generally accepted: 
• Preterm neonate  Born at < 37 weeks gestation 
• Term neonate   Born at 37 to 42 weeks gestation 
• Post-term neonate  Born at ≥42 weeks gestation 
• Neonate   From 0 up to 28 days of age (or first 4 weeks of life) 
• Infant    From 28 days up to 24 months of age 
• Child    From 2 years up to 12 years of age 
• Adolescent   From 12 years up to 18 years of age 
 
Key Pharmacokinetic Differences  
For neonates, infants and children in particular, their stage of development is critical to how they are 
treated.  
Absorption 
Neonates 
Oral delivery of drugs is unreliable due to various factors, including poor stomach emptying, higher pH 
environment in the stomach and differences in enzymes in the intestinal wall that metabolise drugs. 
This makes intravenous delivery the preferred route for most drugs. Other routes include: 
• Rectal. May lead to slow and unpredictable absorption. Can be used for simple pain relief (for 
example, paracetamol suppositories) or treatment of seizures (for example, diazepam rectal 
tubes) 
• Intramuscularly (for example, vitamin K or naloxone). Rate and extent of absorption is 
dependent on blood flow to the muscle. May cause muscle damage in premature neonates if 
the volume administered is too high 
• Buccal (for example, glucose gel for hypoglycaemia) 
• via the trachea (for example, surfactants or caffeine to aid breathing) 
• Transdermal. While not commonly used, it should be noted that preterm neonates of 28 
weeks’ gestation or less have very thin stratum corneum and hence substances in contact with 
their skin could potentially be highly absorbed. 
Infants and children 
Oral absorption of drugs is affected by factors such as the gastric and intestinal pH and intestinal 
transit time. Gastric emptying approaches adult values from about 6 months of age, with gastric acid 
secretion becoming comparable with adult values in the second year of life. Generally, the rate at 
which drugs are absorbed is expected to be slower in young infants (up to around 6 months of age) 
than in older children. Other routes of administration which have age considerations are: 
• Intramuscular – absorption is much faster than in the neonate due to increased blood flow 
• Transdermal – greater perfusion and hydration of the skin, relative to adults, can influence 
absorption 
• Rectal – a greater number of rectal contraction in infants may lead to greater likelihood of 
doses being ejected before absorption can occur 
Distribution 
Neonates and infants 
For those born preterm, the neonatal period may extend to several months, with those born more 
than 10 weeks early or having intra-uterine growth retardation having little body fat. Conversely, 
where the mother has diabetes, the neonate may be larger than normal with greater levels of fat than 
normal. This has direct relevance to the partitioning of drug into body compartments as a 
consequence of its physiochemical characteristics for example, hydrophilicity or lipophilicity. 
Changes in body composition during the first year of life are the most dramatic. Compared with adults, 
neonates and infants have large extracellular fluid and total body water spaces, which means that 
drugs that distribute into these spaces (for example, aminoglycosides) have a lower plasma 
concentration for an equivalent dose per kg.  In other words, for these medicines, higher doses of such 
medicines are needed to achieve the same plasma concentration. 
Plasma proteins are also different in both composition and quantity in neonates and young infants. A 
number of factors, including lower albumin and total plasma protein levels lead to a generally higher 
free fraction of protein-bound drugs. This means that for drugs such as phenytoin, phenobarbital and 
furosemide, lower plasma concentrations may be required to achieve the same therapeutic effect as 
in adult patients. Additionally, neonates may have a functionally incomplete blood-brain barrier, 
which may result in greater levels of drug reaching the central nervous system. 
Children 
Differences in the distribution of drugs between children and adults are of less significance, with any 
variation normally being less important than the potential effect of the disease state itself on the 
distribution process. 
Metabolism 
Drug metabolism can be divided into phase 1 and phase 2 reactions; phase 1 being primarily 
concerned with making the drug more polar and amenable to being conjugated to a water-soluble 
group in phase 2. This second phase normally leads to an inactive compound that can be excreted 
from the body. Most of these reactions occur in the liver, with phase 1 reactions using enzymes in the 
cytochrome P450 (CYP) family.     
Neonates and infants 
The level of enzymes involved in drug metabolism are either negligible or much reduced in a neonate 
at term, compared with adult values. Changes in the expression of CYP enzymes occur from birth, with 
half-lives of drugs metabolised by these enzymes rapidly falling in response to increased expression. 
For example, the half-life of phenytoin has been reported to decrease from 75 hours for a preterm 
neonate at birth, to 24-48 hours for term neonates and then to 8 hours by 14 days after birth. Similarly, 
theophylline has been shown to decrease in a linear fashion with postnatal age, with a half-life 
reduction from 8-18 hours in term neonates, to 3-4 hours at 48 weeks’ postnatal age. 
Differences in metabolism are not solely confined to phase 1 reactions; several phase 2 reactions are 
also age-dependent. The best known of these is how neonates and young infants handle paracetamol, 
with conjugation reactions differing from adults in that sulfate, and not glucuronide, is the 
predominant group conjugated. This compensatory pathway means the half-life of paracetamol 
appears normal in neonates, even though they are unable to use glucuronide in their paracetamol 
metabolism to the same extent as adults. 
Overall, the rate of metabolism is often dependent on age, with dose adjustments being necessary to 
deliver the same therapeutic outcome as metabolic systems develop. 
Children 
Older infants and young children metabolism may be higher than in adults, leading to potentially 
higher doses needed on a mg per kg basis. For example, one enzyme (CYP3A4), that is involved in the 
metabolism of a number of drugs, including carbamazepine, is known to show greater activity in 
children before gradually moving to adult values during adolescence. Other studies have shown the 
need for greater theophylline doses at in older infants and children, compared with older adolescents 
and adults, due to enhanced metabolic clearance. 
Excretion 
Neonates and infants 
The renal excretion of drugs depends on three processes: glomerular filtration, tubular secretion and 
tubular reabsorption. In preterm neonates, the kidney is still developing, with nephron maturation 
being the most important determinant of renal function at birth. When adjusted for body surface area, 
the glomerular filtration rate of term neonates rapidly increases from around 20 mL/min at birth, 
doubling in the first 2 weeks of life and approaching adult values by 3 to 5 months.  
Tubular secretion and reabsorption are much slower to mature, only reaching adult values in around 
15 and 24 months respectively. This may have an impact on some drugs that are actively secreted in 
the renal tubules, such as digoxin. In general, for drugs that are mostly cleared by the kidney, 
immature function results in lower excretion of drugs and hence longer half-lives in the body.  
 
Role of the pharmacist 
 
Pharmacists are well placed to ensure medicine use in the young is safe, effective and, as much as is 
possible, evidence-based. We will look in more depth at medicines use in children in the next article 
(Part 2). Given the vulnerable nature of children with their distinctive physiology and age-related drug 
handling capabilities, it is important that all healthcare professionals, including pharmacists, ensure 
that the benefits of any medicine are not outweighed by the risks. In order to assess this, good 
information is essential; hence, reference sources such as the British National Formulary for Children 
(BNFC) are indispensable. Where information is not readily available, for example, with unlicensed or 
off-label medicine use, medicines information services should be contacted to determine the 
appropriateness of the treatment. Other useful web addresses are provided below. It is also important 
that pharmacists understand how key pieces of legislation may apply during consultations involving 
children (such as safeguarding children and patient consent). Some useful resources have been 
provided below. 
 
It is also a key part of the pharmacist’s role to provide good quality information to patients or carers, 
such as how to use their medicines, what potential side-effects or adverse reactions may occur and 
what to do if doses are missed or too much is taken. An important and valuable resource in this regard 
is the Medicines for Children website (www.medicinesforchildren.org.uk). Medicines for Children is a 
partnership programme by the Royal College of Paediatrics and Child Health (RCPCH), Neonatal and 
Paediatric Pharmacists (NPPG) and WellChild charity, which provides quality assured information 
about medicines for parents or carers of children. The website contains hundreds of leaflets that can 
be downloaded as pdfs and also has some video content showing how to administer medicines to 
children. It is worth noting that links to specific leaflets are included, where available, in the “Patient 
and Carer Advice” section of monographs within the BNFC. 
 
Useful resources:  
• National Institute for Health and Care Excellence (NICE): https://www.nice.org.uk/ 
• NICE Clinical Knowledge Summaries (CKS): cks.nice.org.uk/ 
• Cochrane Library: www.cochranelibrary.com/ 
• electronic Medicines Compendium (eMC): https://www.medicines.org.uk/ 
• NHS Choices: www.nhs.uk/ 
• BNFC, available from https://www.bnf.org/ or 
https://www.evidence.nhs.uk/formulary/bnfc/current or 
https://www.medicinescomplete.com/ 
• British Paediatric Surveillance Unit (BPSU): http://www.rcpch.ac.uk/bpsu 
• UK Medicines for Children Research Network (MCRN): http://www.priomedchild.eu/whats-
going-on/networks/the-uk-medicines-for-children-research-network-mcrn/ 
• Neonatal and Paediatric Pharmacists Group (NPPG): https://www.nppg.org.uk/ 
• Medicines for Children: Medicinesforchildren.org  
• Focus on safeguarding children and vulnerable adults: 
https://www.pharmacyregulation.org/regulate/article/focus-safeguarding-children-and-
vulnerable-adults 
• Pharmaceutical Society of Northern Ireland. Professional standards and guidance for patient 
consent: http://www.psni.org.uk/wp-
content/uploads/2012/09/StandardsonPatientConsent-revised24FEB2016.pdf 
• General Pharmaceutical Society. Guidance on consent: 
https://www.pharmacyregulation.org/sites/default/files/guidance_on_consent_08.09.14.pd
f 
 
Conclusion 
 
Many important differences exist between adults and children, particularly those in the first years of 
life. The developing child has important pharmacokinetic characteristics that need to be accounted 
for when using medicines in children. For pharmacists, knowledge of these changes is important in 
ensuring that medicines are used safely and effectively. In the next article, we will focus specifically 
on the use of medicines in children, looking particularly at factors pharmacists should consider when 
providing over-the-counter medicines for use in children.  
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